IN2014DN05912A - - Google Patents
Info
- Publication number
- IN2014DN05912A IN2014DN05912A IN5912DEN2014A IN2014DN05912A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A IN 5912DEN2014 A IN5912DEN2014 A IN 5912DEN2014A IN 2014DN05912 A IN2014DN05912 A IN 2014DN05912A
- Authority
- IN
- India
- Prior art keywords
- aminoamidine polymers
- aminoamidine
- polymers
- preparing
- polynucleotides
- Prior art date
Links
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 7
- 229920000642 polymer Polymers 0.000 abstract 7
- 238000012377 drug delivery Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000002527 isonitriles Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000004033 plastic Substances 0.000 abstract 1
- 229920003023 plastic Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/04—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with acyclic or carbocyclic compounds
- C08G12/06—Amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G12/00—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen
- C08G12/02—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes
- C08G12/26—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds
- C08G12/34—Condensation polymers of aldehydes or ketones with only compounds containing hydrogen attached to nitrogen of aldehydes with heterocyclic compounds and acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polyamides (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Abstract
a Aminoamidine polymers and methods of preparing a aminoamidine polymers by reacting by reacting one or more amines with one or more isocyanides and one or more aldehydes are described. Methods of preparing a aminoamidine polymers from commercially available starting materials are also provided wherein the starting materials are racemic or stereochemically pure. a Aminoamidine polymers or salt forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems and for other purposes as well such as for example coatings additives excipients plastics and materials etc. Given the amino moiety of these a aminoamidine polymers they are particularly suited for the delivery of polynucleotides. Complexes micelles liposomes or particles containing the inventive a aminoamidine polymers and polynucleotides can be prepared. The inventive a aminoamidine polymers may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576899P | 2011-12-16 | 2011-12-16 | |
| PCT/US2012/069961 WO2013090861A1 (en) | 2011-12-16 | 2012-12-15 | Alpha-aminoamidine polymers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05912A true IN2014DN05912A (en) | 2015-06-05 |
Family
ID=47501483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5912DEN2014 IN2014DN05912A (en) | 2011-12-16 | 2012-12-15 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9872911B2 (en) |
| EP (1) | EP2791210A1 (en) |
| CN (1) | CN104245794A (en) |
| AU (1) | AU2012351967A1 (en) |
| BR (1) | BR112014014599A2 (en) |
| CA (1) | CA2859205A1 (en) |
| EA (1) | EA201491185A1 (en) |
| IN (1) | IN2014DN05912A (en) |
| WO (1) | WO2013090861A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060403A2 (en) | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| WO2010043049A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| MX2011011023A (en) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog. |
| RU2012103240A (en) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | MULTI-DIMENSIONAL PEPTIDE CONJUGATES AND THEIR APPLICATION |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (en) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USES THEREOF |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (en) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Terminally modified rna |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP3155116A4 (en) | 2014-06-10 | 2017-12-27 | Massachusetts Institute Of Technology | Method for gene editing |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| JP7450945B2 (en) | 2018-08-30 | 2024-03-18 | テナヤ セラピューティクス， インコーポレイテッド | Cardiac cell reprogramming using myocardin and ASCL1 |
| WO2020061295A1 (en) * | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| EP3997226A1 (en) | 2019-07-11 | 2022-05-18 | Tenaya Therapeutics, Inc. | Cardiac cell reprogramming with micrornas and other factors |
| US11773391B2 (en) | 2020-04-01 | 2023-10-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19 |
| CN112876677B (en) * | 2020-12-29 | 2022-05-06 | 浙江大学杭州国际科创中心 | A kind of dopamine functionalized poly (beta-amino ester) and its preparation method and application |
| CN114315889B (en) * | 2021-12-20 | 2024-03-22 | 广东万木新材料科技有限公司 | Difunctional organic disilane ether compound and synthesis method thereof |
| CN117003792B (en) * | 2023-07-11 | 2025-11-07 | 西北工业大学 | P-hydroxybenzaldehyde compound and method for preparing octreotide with assistance of p-hydroxybenzaldehyde compound |
| CN118955424B (en) * | 2024-07-31 | 2026-01-02 | 首都医科大学附属北京胸科医院 | A N-amide-substituted phenoloxazine compound, its preparation and application |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5155174A (en) | 1989-05-08 | 1992-10-13 | American Cyanamid Company | Surface-modified polyacrylonitrile fibrous substrates |
| US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
| SE519326C2 (en) | 1999-11-22 | 2003-02-11 | Astrazeneca Ab | Functionalized polymeric reagents comprising an acid labile isonitrile moiety and process for its preparation |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| EP2447370B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20030211139A1 (en) * | 2002-05-07 | 2003-11-13 | Thierry Legon | Dispersions of lipid particles for use as therapeutic and cosmetic agents and intracellular delivery vehicles |
| TW200640493A (en) | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| US8808681B2 (en) | 2006-06-05 | 2014-08-19 | Massachusetts Institute Of Technology | Crosslinked, degradable polymers and uses thereof |
| EP2046266A4 (en) | 2006-07-21 | 2009-11-04 | Massachusetts Inst Technology | MODIFIED EXTREMITE POLY (BETA-AMINO ESTERS) AND USES THEREOF |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP2200652B1 (en) | 2007-09-27 | 2018-03-21 | Children's Medical Center Corporation | Microbubbles and methods for oxygen delivery |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
-
2012
- 2012-12-15 IN IN5912DEN2014 patent/IN2014DN05912A/en unknown
- 2012-12-15 AU AU2012351967A patent/AU2012351967A1/en not_active Abandoned
- 2012-12-15 BR BR112014014599A patent/BR112014014599A2/en not_active IP Right Cessation
- 2012-12-15 CN CN201280069821.XA patent/CN104245794A/en active Pending
- 2012-12-15 CA CA2859205A patent/CA2859205A1/en not_active Abandoned
- 2012-12-15 US US14/364,028 patent/US9872911B2/en not_active Expired - Fee Related
- 2012-12-15 EP EP12809954.6A patent/EP2791210A1/en not_active Withdrawn
- 2012-12-15 EA EA201491185A patent/EA201491185A1/en unknown
- 2012-12-15 WO PCT/US2012/069961 patent/WO2013090861A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2791210A1 (en) | 2014-10-22 |
| AU2012351967A1 (en) | 2014-07-17 |
| US9872911B2 (en) | 2018-01-23 |
| CN104245794A (en) | 2014-12-24 |
| US20140322309A1 (en) | 2014-10-30 |
| BR112014014599A8 (en) | 2017-06-13 |
| BR112014014599A2 (en) | 2017-06-13 |
| WO2013090861A1 (en) | 2013-06-20 |
| CA2859205A1 (en) | 2013-06-20 |
| WO2013090861A8 (en) | 2013-08-22 |
| EA201491185A1 (en) | 2015-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05912A (en) | ||
| MX353900B (en) | Aminoalcohol lipidoids and uses thereof. | |
| JP2016222689A5 (en) | Synthetic peptide and dry powder drug delivery system | |
| IN2014DN00101A (en) | ||
| EP4331667A3 (en) | Compositions comprising a delivery agent and preparation thereof | |
| MX362432B (en) | Pegylated oxm variants. | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| EP2771043A4 (en) | METHODS OF DRUG DELIVERY | |
| JP2017533218A5 (en) | ||
| MX2013007537A (en) | Pharmaceutical formulation comprising a biopharmaceutical drug. | |
| MX2010006799A (en) | Benzofuropyrimidinones as protein kinase inhibitors. | |
| PE20170312A1 (en) | THERAPEUTIC NANOPARTICLES INCLUDING A THERAPEUTIC AGENT, AND METHODS FOR THEIR PREPARATION AND USE | |
| EP4286400A3 (en) | Improved peptide pharmaceuticals | |
| EP2595633A4 (en) | METHODS OF INTRAVENOUSLY DELIVERING GLYBURIDE AND OTHER MEDICAMENTS | |
| EP3747891A3 (en) | Compositions and methods for conjugating oligonucleotides | |
| PH12013500223A1 (en) | Oral care product and methods of use and manufacture thereof | |
| ATE530188T1 (en) | COMPOSITIONS AND METHODS FOR DELIVERING ANTI-CANCER AGENTS | |
| MX376192B (en) | INJECTION MOLDED ARTICLE. | |
| MX365373B (en) | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them. | |
| IN2014MN02248A (en) | ||
| SA517381298B1 (en) | Pharmaceutical formula with improved stability | |
| GB201002413D0 (en) | Nucleic acid complexes | |
| EP2666773A8 (en) | Organic amine salts of azilsartan, preparation method and use thereof | |
| MX2013013691A (en) | A sustained -release composition containing a melanocortin receptor ligand as the active ingredient. | |
| PH12014502407B1 (en) | New alfentanil composition for the treatment of acute pain |